Clinical manifestations
| Clinical Manifestations | Male (N=353) | Women (N=3298) | P value | |
|---|---|---|---|---|
| N (%) | N (%) | |||
| Systemic | Lymphadenopathy | 49 (14%) | 320 (9,9%) | 0,02 |
| Splenomegaly | 19 (5,5%) | 99 (3,1%) | 0,02 | |
| Cutaneous | Exanthema | 190 (54,3%) | 2180 (67,1%) | <0,0001 |
| Alopecia | 54 (15,8%) | 1229 (38%) | <0,0001 | |
| Osteoarticular | Erosive arthritis | 20 (5,8%) | 342 (10,5%) | 0,01 |
| Avascular bone necrosis | 30 (8,5%) | 121 (3,7%) | <0,0001 | |
| Pulmonary | Pleural fibrosis | 8 (2,3%) | 25 (0,8%) | <0,0001 |
| Pulmonary thromboembolism | 18 (5,1%) | 86 (2,6%) | 0,01 | |
| Cardiovascular | Acute myocardial infarction | 24 (6,9%) | 47 (1,4) | <0,0001 |
| Pericarditis | 15 (4,3%) | 59 (1,8%) | <0,0001 | |
| Peripheral vascular | Deep vein thrombosis | 24 (6,9%) | 119 (3,7%) | <0,0001 |
| Raynaud | 80 (23,7%) | 1114 (35%) | <0,0001 | |
| Renal | Lupus nephritis | 156 (44,8%) | 933 (29%) | <0,0001 |
| Proteinuria =3,5g/24hs | 21 (6,1%) | 114 (3,6%) | 0,02 | |
| Terminal renal insufficiency | 16 (4,7%) | 82 (2,6%) | 0,03 | |
| Neurological | Seizures | 32 (9,2%) | 156 (4,8%) | <0,0001 |
| Immunology | Ac anti DNA positive | 271 (78,6%) | 2342 (72,9%) | 0,02 |
| AC anti RO positive | 94 (27,5%) | 1300 (40,8%) | <0,0001 | |